HAE treatment Ekterly hits $49M sales in months since July launch
Kalvista says demand for oral therapy continues strong
Written by |
Kalvista Pharmaceuticals saw approximately $49 million in global revenue from Ekterly (sebetralstat) in the treatment’s initial six months on the market, according to a year-end update.
Approved in mid-2025 as the first oral on-demand treatment for hereditary angioedema (HAE) in the U.S. and Europe, the therapy generated sales of about $35 million in the year’s final quarter, the company said.
“We are extremely pleased with our performance since launching Ekterly in July, which reflects steady execution, growing utilization, and continued momentum across our business,” Ben Palleiko, CEO of Kalvista, said in a company press release.
Kalvista said it had recorded 1,318 patient start forms and activated 580 prescribers as of Dec. 31. By the final months of 2025, Ekterly was generating more revenue from prescription refills than from initial prescriptions.
“Demand for Ekterly remains steady, supported by strong prescriber engagement and positive patient and provider experiences,” said Nicole Sweeny, chief commercial officer of Kalvista. “Utilization has increased consistently since we launched in July, and we are particularly encouraged by the continued growth of patient refills, which now make up the majority of total sales. These trends reflect growing real-world familiarity and patient satisfaction with Ekterly. We remain focused on ensuring reliable access, maintaining operational excellence, and continuing to support the HAE community as Ekterly becomes the foundational HAE treatment.”
Demand remains strong
“Fundamental demand has remained strong, with some effects from seasonal variability, and we are encouraged by the continued high level of interest in switching to Ekterly,” Palleiko said.
HAE is a genetic disorder characterized by attacks of swelling due to the overproduction of a signaling molecule called bradykinin. Ekterly, which carries a list price of $16,720 per dose, is designed to control swelling by reducing levels of this molecule.
The therapy has been approved in the U.S., the European Union, Switzerland, and the U.K. since July as an on-demand treatment for patients with HAE aged 12 and older. The approvals were based on clinical trial data showing that on-demand Ekterly was more effective than a placebo at providing symptom relief from swelling attacks in adults and adolescents with HAE.
Kalvista recently announced data from KONFIDENT-KID (NCT06467084), a Phase 3 study testing a formulation of Ekterly that dissolves on the tongue in children with HAE aged 2 to 11. The findings showed that the therapy was well tolerated and provided relief from symptoms brought on by attacks.
Kalvista plans to use these data as a basis to request regulatory bodies to expand the approvals of Ekterly for children as young as 2. The company said it is also working to make Ekterly accessible to HAE patients in other markets.
“With Ekterly rapidly emerging as the preferred on-demand HAE treatment, we remain committed to making it accessible to all people living with HAE, including pediatric patients aged 2-11 years,” Palleiko said, adding that the company plans to file an application seeking approval for this age range in the U.S. in the third quarter.
The company has a patient support program, Kalvista Cares, that helps eligible patients with access, insurance navigation, and personalized resources. The program includes copay assistance for commercially insured patients.
